أعرض في EDS

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

التفاصيل البيبلوغرافية
العنوان:	304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial
المؤلفون:	F-C Bidard, Anne Pradines, Suzette Delaloge, Delphine Loirat, Valérie Delecroix, S. Nguyen, M-A Mouret-Reynier, Thomas Bachelot, C. Greilsamer, J-S. Frenel, Jérôme Lemonnier, C. Levy, A-C. Hardy-Bessard, T. de La Motte Rouge, Florence Dalenc, N. Bonichon-Lamichhane, Frédérique Berger, Barbara Pistilli, Sibille Everhard, Céline Callens
المصدر:	Annals of Oncology. 31:S364
بيانات النشر:	Elsevier BV, 2020.
سنة النشر:	2020
مصطلحات موضوعية:	Aromatase inhibitor, business.industry, medicine.drug_class, First line, PALB2, Hematology, Palbociclib, medicine.disease, Metastatic breast cancer, Germline mutation, Oncology, Cancer research, Medicine, business, Estrogen receptor alpha
تدمد:	0923-7534
DOI:	10.1016/j.annonc.2020.08.406
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_________::8f67baf9d6f23c6305b46fa92a5c40ff https://doi.org/10.1016/j.annonc.2020.08.406
Rights:	OPEN
رقم الانضمام:	edsair.doi...........8f67baf9d6f23c6305b46fa92a5c40ff
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	09237534
DOI:	10.1016/j.annonc.2020.08.406